



MERCK

**REGISTER NOW!**

# Virtual ADC & Bioconjugation Symposium

November 16, 2021  
15:30-18:00 CET



The life science business of Merck KGaA,  
Darmstadt, Germany operates as  
MilliporeSigma in the U.S. and Canada.

# Join the ADC & Bioconjugation Symposium 2021

100% DIGITAL

You are cordially invited to participate in our virtual 2021 ADC Symposium. This technical symposium is a unique opportunity to discover enabling technologies and today's trends in drug development and manufacturing.

## Topics of this symposium will cover:

- CMC regulatory considerations
- Control strategy development
- QbD: Applying PAT in ADC processes
- Novel technology for solubility enhancement
- Payload cores to accelerate clinical development

Register now and learn from industry experts and your peers about today's advancements in the ADC space.

## Confirmed speakers\*:

**Matthias Joehnck** (Moderating Chair), PhD, Senior Director, Head of Life Science Actives & Formulations R&D, Merck KGaA, Darmstadt, Germany

**Andrea Ruggiero**, PhD, Director - GRA CMC Regulatory Intelligence, Merck KGaA, Darmstadt, Germany

**André Dumetz**, PhD, Scientific Director - Biopharm Downstream PD-3, R&D Platform Technology & Science, GlaxoSmithKline

**Haowei Song**, PhD, Principal Scientist for Novel Modality R&D, Merck KGaA, Darmstadt, Germany

**Carl Deutsch**, PhD, Director ADC Chemistry and Cell Biology, Merck KGaA, Darmstadt, Germany

**David Goeddel**, PhD, Director API R&D, Merck KGaA, Darmstadt, Germany

**The event is free of charge, though registration is required**

\* Agenda subject to change. Attendance to the ADC & Bioconjugation Symposium is limited and available to pharma/biopharma manufacturers only.

The offer does not extend to any company that provides products or services to the pharma/biopharma industry. Merck reserves the right to revoke or refuse participation at any times.

[Learn More & Register Today >>](#)

# Agenda

TIME	TOPIC	SPEAKER	COMPANY
15:30	<b>Welcome and Introduction</b>	Matthias Joehnck, PhD	Merck KGaA, Darmstadt, Germany
15:40	<b>CMC Regulatory Considerations for ADCs</b>	Andrea Ruggiero, PhD	Merck KGaA, Darmstadt, Germany
16:05	<b>ADC Control Strategy Development: Toward a Well-Characterized Process that Ensure Quality and Reliable Supply of Medicines for the Patient</b>	André Dumetz, PhD	GlaxoSmithKline
16:30	<b>Quality by Design: Applying Process Analytical Technology in ADC processes</b>	Haowei Song, PhD	Merck KGaA, Darmstadt, Germany
16:55	<b>Break</b>		
17:05	<b>ChetoSensor™ Technology Platform: Consider it DisSolved</b>	Carl Deutsch, PhD	Merck KGaA, Darmstadt, Germany
17:30	<b>Technological advancements to accelerate GMP payload availability and improved ADC solubility</b>	David Goeddel, PhD	Merck KGaA, Darmstadt, Germany
17:55	<b>Closing remarks</b>	Matthias Joehnck, PhD	Merck KGaA, Darmstadt, Germany
18:00	<b>End</b>		